Table 1.
Pharmacokinetic parameters (mean ± 1 SD, where applicable) after subcutaneous and intravenous dosing of cefovecin
| Squirrel monkeys (n = 3) | Cynomolgus macaques (n = 3) | Rhesus macaques (n = 3) | Beagle dogs (n = 2) | Published data from beagle dogs (n = 12)a | |
| Subcutaneous dosing (8 mg/kg) | |||||
| Maximal plasma concentration (µg/mL) | 42 ± 9 | 46 ± 6 | 47 ± 8 | 85 | 121 ± 51 |
| Time (h) to maximal plasma concentration (range) | 0.5 (0.5) | 1 (1) | 2 (0.2–4) | 2 (2) | 6.2 ± 3.0 |
| AUC0 to 96 h (µg /mL/h) | 128 ± 38 | 468 ± 97 | 520 ± 70 | 4853 | not done |
| Terminal half-life (h) | 2.6 ± 0.1 | 6.3 ± 1.8 | 8.0 ± 0.6 | 102 | 133 ± 16 |
| Intravenous dosing (2 mg/kg) | |||||
| Terminal half life of intravenous dose (h) | 8.5 ± 1.2 | 136 ± 12 | |||
| Clearance (mL/h/kg) | 15 ± 5 | 0.76 ± 0.13 | |||
| Estimate of unbound clearance (mL/h/kg) | 400–700 | 36 | |||
| Volume of distribution (L/kg) | 0.16 ± 0.02 | 0.122 ± 0.011 | |||
| Bioavailability | 82 ± 19 | 99–107 |
a
From reference 12.